Figure S3 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors Through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

Ping Jin,Xin Li,Yu Xia,Huayi Li,Xiaoting Li,Zong-Yuan Yang,Zhen Wang,Cheng Xu,Tian Fang,Dongchen Zhou,Xiaoming Xiong,Si-Yuan Wang,Sen Xu,Qinglei Gao

DOI: https://doi.org/10.1158/1535-7163.22495260

2023-01-01

Abstract:Figure S3, related to Fig 4

What problem does this paper attempt to address?

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:<p>PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.</p>
Figure S4 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors Through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

Xiaoming Xiong

DOI: https://doi.org/10.1158/1535-7163.mct-22-0396

2023-01-01

Molecular Cancer Therapeutics

Abstract:AbstractTherapy-induced senescence (TIS) is common in tumor cells treated with PARP inhibitors (PARPis) and can serve as a promising target for improving PARPi efficacy. However, whether stromal components within the tumor microenvironment undergo TIS caused by PARPis and contribute to consequential treatment failure remain unclear. We previously revealed that PARPis triggered a senescence-like secretory phenotype in stromal fibroblasts. Here, we further explored PARPi-induced senescence in the stroma, its contribution to PARPi resistance, and opportunities to leverage stromal TIS for improved PARPi sensitivity. In this study, we demonstrated that tumor tissues from patients treated with neoadjuvant PARPis showed a significant senescence-like phenotype in the stroma. Moreover, PARPi-induced senescent cancer-associated fibroblasts (CAFs) displayed a senescence-associated secretory phenotype (SASP) profile that was sufficient to induce tumor resistance to PARPis in both homologous recombination–deficient (HRD) and –proficient ovarian cancer cells. Using the GLAD4U database, we found that bepotastine, an approved H1-antihistamine, inhibited the SASP of PARPi-primed CAFs at clinical serum concentrations. We further demonstrated that bepotastine attenuated fibroblast-facilitated tumor resistance to PARPis in three-dimensional organotypic cultures and HRD-positive patient-derived xenograft models. Mechanistically, bepotastine suppressed PARPi-triggered SASP by inhibiting NF-κB signaling independent of the histamine H1 receptor. Taken together, our results highlight the importance of stromal TIS and SASP in PARPi resistance, and targeting SASP with bepotastine may be a promising therapeutic option for improving PARPi sensitivity in ovarian cancer.
Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
Figure S7 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/0008-5472.27231238

2024-01-01

Abstract:Figure S7 illustrates the enhanced sensitivity of breast cancer cells to talazoparib by FANCI knockdown.
Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497784.v1

2023-01-01

Abstract:PDF file - 68K, Figure S2: Effect of BMS-777607 on breast cancer cell growth and apoptotic death.
Supplementary Figure 3 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497781

2023-01-01

Abstract:PDF file - 59K, Figure S3: Effect of PHA665752, Compound-I, and BMS-777607 on induction of polyploidy in breast cancer cells.
Supplementary Table 1 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma <i>in Vivo</i>

Xiao-yan Zhang,Jun Chen,Yu-fang Zheng,Xiao-ling Gao,Yu Kang,Jia-chi Liu,Ming-jun Cheng,Hong Sun,Cong-jian Xu

DOI: https://doi.org/10.1158/0008-5472.22377926

2023-01-01

Abstract:Supplementary Figure 1 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma In vivo
Figure S2 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/0008-5472.27231253

2024-01-01

Abstract:Figure S2 depicts the expression patterns of FANCI among breast cancer patient groups based on clinical parameters.
Figure S5 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/0008-5472.27231244

2024-01-01

Abstract:Figure S5 presents a comprehensive analysis of the interaction between FANCI and PARP1.
Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Dongping Wei,Leslie A. Parsels,David Karnak,Mary A. Davis,Joshua D. Parsels,Amanda C. Marsh,Lili Zhao,Jonathan Maybaum,Theodore S. Lawrence,Yi Sun,Meredith A. Morgan

DOI: https://doi.org/10.1158/1078-0432.22450100

2023-01-01

Abstract:PDF file - 52K, LB100 causes an increase in pHistone H3 positive cells.
Supplementary Data from Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

Li Liao,Yin-Ling Zhang,Ling Deng,Chao Chen,Xiao-Yan Ma,Lisa Andriani,Shao-Ying Yang,Shu-Yuan Hu,Fang-Lin Zhang,Zhi-Min Shao,Da-Qiang Li

DOI: https://doi.org/10.1158/0008-5472.22433349

2023-01-01

Abstract:Supplementary figures and tables
Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Tao Zuo,Ta-Ming Liu,Xun Lan,Yu-I Weng,Rulong Shen,Fei Gu,Yi-Wen Huang,Sandya Liyanarachchi,Daniel E. Deatherage,Pei-Yin Hsu,Cenny Taslim,Bhuvaneswari Ramaswamy,Charles L. Shapiro,Huey-Jen L. Lin,Alfred S. L. Cheng,Victor X. Jin,Tim H.-M. Huang

DOI: https://doi.org/10.1158/0008-5472.22389515.v1

2023-01-01

Abstract:Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer
Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Dan Su,Ruobing Wang,Guangyu Chen,Chen Ding,Yueze Liu,Jinxin Tao,Yuanyang Wang,Jiangdong Qiu,Wenhao Luo,Guihu Weng,Gang Yang,Taiping Zhang

DOI: https://doi.org/10.1158/0008-5472.26711161.v1

2024-01-01

Abstract:Supplementary Fig. S5
Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Li Lin,Brian Hutzen,Mingxin Zuo,Sarah Ball,Stephanie Deangelis,Elizabeth Foust,Bulbul Pandit,Michael A. Ihnat,Satyendra S. Shenoy,Samuel Kulp,Pui-Kai Li,Chenglong Li,James Fuchs,Jiayuh Lin

DOI: https://doi.org/10.1158/0008-5472.22387140.v1

2023-01-01

Abstract:Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Yajing Liu,Monika L. Burness,Rachel Martin-Trevino,Joey Guy,Shoumei Bai,Ramdane Harouaka,Michael Brooks,Shang Li,Alex Fox,Tahra Luther,April Davis,Trenton L. Baker,Justin A. Colacino,Shawn G. Clouthier,Zhi‐Ming Shao,Max S. Wicha,Suling Liu

DOI: https://doi.org/10.1158/1078-0432.22460774.v1

2023-01-01

Abstract:Supplementary figures 1-8 legends
Supplementary Table 3 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma in Vivo

Xiao-yan Zhang,Jun Chen,Yu-fang Zheng,Xiao-ling Gao,Yu Kang,Jia-chi Liu,Ming-jun Cheng,Hong Sun,Cong-jian Xu

DOI: https://doi.org/10.1158/0008-5472.22377917

2023-01-01

Abstract:Supplementary Table 3 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma In vivo
Supplementary Figures 1-4 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Li Lin,Brian Hutzen,Mingxin Zuo,Sarah Ball,Stephanie Deangelis,Elizabeth Foust,Bulbul Pandit,Michael A. Ihnat,Satyendra S. Shenoy,Samuel Kulp,Pui-Kai Li,Chenglong Li,James Fuchs,Jiayuh Lin

DOI: https://doi.org/10.1158/0008-5472.22387134.v1

2023-01-01

Abstract:Supplementary Figures 1-4 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125052.v1

2024-01-01

Abstract:Supplementary Video S2 is related to Figure 5 (Olaparib-only group).
A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling

Chia-Hsun Fang,Yi-Te Lin,Chi-Ming Liang,Shu-Mei Liang

DOI: https://doi.org/10.1186/s12929-020-00638-x

2020-03-13

Abstract:Background: The underlying mechanism involved in ovarian cancer stemness and chemoresistance remains largely unknown. Here, we explored whether the regulation of c-Kit and plasma membrane prohibitin (PHB) affects ovarian cancer stemness and chemotherapy resistance. Methods: Mass spectrum analysis and an in vitro kinase assay were conducted to examine the phosphorylation of PHB at tyrosine 259 by c-Kit. The in vitro effects of c-Kit on membrane raft-PHB in ovarian cancer were determined using tissue microarray (TMA)-based immunofluorescence, western blotting, immunoprecipitation, colony and spheroid formation, cell migration and cell viability assays. In vivo tumor initiation and carboplatin treatment were conducted in nude mice. Results: We found that c-Kit and PHB colocalized in the raft domain and were positively correlated in human ovarian serous carcinoma. c-Kit interacted with PHB and facilitated the phosphorylation of PHB at tyrosine 259 (phospho-PHBY259) in the membrane raft to enhance ovarian cancer cell motility. The generation of SKOV3GL-G4, a metastatic phenotype of SKOV3 green fluorescent protein and luciferase (GL) ovarian cancer cells, in xenograft murine ascites showed a correlation between metastatic potential and stem cell characteristics, as indicated by the expression of c-Kit, Notch3, Oct4, Nanog and SOX2. Further study revealed that after activation by c-Kit, raft-phospho-PHBY259 interacted with Notch3 to stabilize Notch3 and increase the downstream target PBX1. Downregulation of raft-phospho-PHBY259 increased the protein degradation of Notch3 through a lysosomal pathway and inhibited the β-catenin-ABCG2 signaling pathway. Moreover, raft-phospho-PHBY259 played an important role in ovarian cancer stemness and tumorigenicity as well as resistance to platinum drug treatment in vitro and in vivo. Conclusions: These findings thus reveal a hitherto unreported interrelationship between c-Kit and PHB as well as the effects of raft-phospho-PHBY259 on ovarian cancer stemness and tumorigenicity mediated by the Notch3 and β-catenin signaling pathways. Targeting the c-Kit/raft-phospho-PHBY259 axis may provide a new therapeutic strategy for treating patients with ovarian cancer.

Figure S3 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors Through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Figure S4 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors Through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Figure S7 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure 3 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Table 1 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma &lt;i&gt;in Vivo&lt;/i&gt;

Figure S2 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Figure S5 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Data from Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Supplementary Figure 5 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Table 3 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma in Vivo

Supplementary Figures 1-4 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling

Supplementary Table 1 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma <i>in Vivo</i>